Abstract: The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-associated diseases, disorders and conditions.

Abstract: A method for preparing aluminum foam sandwich material by rotating friction extrusion and electromagnetic pulse hybrid process includes: step 1: preparing the filler; step 2: processing the filler to prepare a plurality of preforms; step 3: clamping and fixing the plurality of preforms to form a preform assembly; step 4: welding the panel on the surface of the preform assembly to form an non-foaming sandwich material; step 5: heating and foaming the non-foaming sandwich material through a foaming mold; step 6: insulating the foaming mold after completion of foaming; injecting cooling water into the foaming mold after completion of insulation to maintain pressure and shape, forming the aluminum foam sandwich material of the required shape. The aluminum foam sandwich material produced by this method has good interface bonding, no adverse interface reaction, high bending resistance, impact resistance, and excellent sound absorption and insulation properties.

Abstract: The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.

Abstract: The disclosure relates to bifunctional CDK-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to a CDK protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of one or more CDK protein in a cell and are thus useful for treating, inhibiting, and preventing CDK-associated diseases, disorders and conditions, including cancers.

Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I? and pharmaceutically acceptable esters or salts thereof.

Abstract: A production method includes providing field-effect transistors; irradiating the field-effect transistors; applying a current to drains of the field-effect transistors for a duration; and applying a same voltage to gates and sources of the field-effect transistors. The voltage is a grounding voltage or a reverse voltage. The field-effect transistors can be in a reverse biased state in a case of cut-off, and electron-hole pairs can be generated at an insulating oxide layer and at an interface between the insulating oxide layer and a semiconductor substrate.

Abstract: A bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests. The method for constructing a bispecific antibody is simple, and avoids the possibility of mismatching between two sets of light chains and heavy chains of a heterologous bispecific antibody, thus the difficulty of antibody purification is reduced, the affinity of the obtained antibody is high, the side effects of induced cytokines are few, and safety is high.

Abstract: An intelligent speed regulation system of a connector production apparatus, including: a CCD detection system includes a CCD industrial camera and a CCD detection software module, wherein the CCD industrial camera is configured to shoot a connector plane picture; the CCD detection software module is configured to analyze and identify the connector plane picture, extract true position error value data and generate an error data table file; an intelligent speed regulation software unit configured to calculate an optimal operation speed value of the connector production apparatus according to the true position error value data of a connector; and a PLC apparatus configured to read the optimal operation speed value of the connector production apparatus, and control actions of mechanisms in the connector production apparatus to finish a speed regulation operation. The operation speed of the apparatus can be automatically adjusted according to quality of a connector product.

Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I? and pharmaceutically acceptable esters or salts thereof.

Abstract: An object of the present invention is to provide a technique of quantitatively measuring physical properties including both viscosity and elasticity. A viscoelasticity measurement system includes a measurement apparatus, a processor, and a display apparatus. The measurement apparatus includes a movable unit continuously pressed against a measurement object, a first sensor outputting acceleration information corresponding to an acceleration of pressing-directional movement of a contact portion of the movable unit with respect to the measurement object, and a second sensor outputting reactive force information corresponding to a reactive force applied to the contact portion of the movable unit with respect to the measurement object. The processor calculates first information on an elasticity component of the measurement object and second information on a viscosity component of the measurement object based on the acceleration information and the reactive force information.

Abstract: An object of the present invention is to provide a durometer enabling a contact portion in contact with an object to perform smooth piston motion. The durometer includes a main body unit including a movable unit pressed continuously against an object to be measured, a first sensor outputting acceleration information corresponding to an acceleration of movement of a contact part of the object to be measured in contact with the movable unit in a pressing direction, a second sensor outputting reactive force information corresponding to a reactive force at the contact part of the object to be measured in contact with the movable unit, a motor, a crank mechanism driven by the motor and causing the main body unit and the movable unit to perform piston motion, and at least one buffering member disposed on a periphery of the main body unit.

Abstract: A tetravalent, homodimer-type bispecific antibody molecule that simultaneously targets immune effector cell antigen CD3 and human epidermal growth factor receptor 2 (Her2); the bispecific antibody molecule comprises, from in sequence from N-terminus to C-terminus, a first single-chain Fv capable of specifically binding to Her2, a second single-chain Fv capable of specifically binding to CD3, and an Fc fragment; the first and second single-chain Fv are connected by means of a connection peptide, and the second single-chain Fv is connected to the Fc directly fragment or is connected by means of a connection peptide; the Fc fragment does not have effector functions such as CDC, ADCC and ADCP. The bispecific antibody may significantly inhibit or kill tumor cells, and has controlled toxic side effects that may be caused by excessive activation of effector cells.

Abstract: An object of the present invention is to provide a technique of quantitatively measuring physical properties including both viscosity and elasticity. A viscoelasticity measurement system includes a measurement apparatus, a processor, and a display apparatus. The measurement apparatus includes a movable unit continuously pressed against a measurement object, a first sensor outputting acceleration information corresponding to an acceleration of pressing-directional movement of a contact portion of the movable unit with respect to the measurement object, and a second sensor outputting reactive force information corresponding to a reactive force applied to the contact portion of the movable unit with respect to the measurement object. The processor calculates first information on an elasticity component of the measurement object and second information on a viscosity component of the measurement object based on the acceleration information and the reactive force information.

Abstract: An object of the present invention is to provide a technique of quantitatively measuring physical properties including both of viscosity and elasticity. A viscoelasticity measurement system includes a measurement apparatus, a processor, and a display apparatus. The measurement apparatus includes a movable unit continuously pressed against a measurement object, a first sensor outputting acceleration information corresponding to an acceleration of pressing-directional movement of a contact portion of the movable unit with respect to the measurement object, and a second sensor outputting reactive force information corresponding to a reactive force applied to the contact portion of the movable unit with respect to the measurement object. The processor calculates first information on an elasticity component of the measurement object and second information on a viscosity component of the measurement object based on the acceleration information and the reactive force information.

Abstract: Disclosed is a bispecific antibody that specifically binds to surface antigens CD3 of immune cells and CD20 antigens on the surfaces of tumor cells, and that can bind to human CD3 with high affinity, inducing T cell proliferation, and mediating tumor cell killing. The bispecific antibody in an in vitro test was able to mediate the specific killing of target cells by T cells. The construction method thereof is simple, avoiding the possibility of mismatch between two sets of light chains and heavy chains of heterobispecific antibodies, thereby reducing the difficulty of antibody purification. The affinity of the obtained antibody is high, the side effects caused by cytokines are small, and safety is high.

Abstract: Provided is a tetravalent, homodimer-type bispecific antibody molecule that targets both immune effector cell antigen CD3 and tumor-related antigen CD19. The bispecific antibody molecule comprises first and second single-chain Fv and Fc fragments in sequence from the N-terminus to the C-terminus, wherein the first single-chain Fv can specifically bind to CD19, the second single-chain Fv can specifically bind to CD3, the first and second single-chains Fv are connected by means of a linker peptide, the second single-chain Fv and Fc fragments are directly connected to each other or connected by means of a linker peptide; and the Fc fragment does not have effector functions such as CDC, ADCC, and ADCP.

Abstract: Provided is a tetravalent homodimeric bispecific antibody molecule simultaneously targeting an immune effector cell antigen CD3 and a tumor-associated antigen, wherein the bispecific antibody molecule contains, in order from N-terminus to C-terminus, a first single chain Fv, a second single chain Fv and a Fc fragment; wherein the first single chain Fv can specifically bind to the tumor-associated antigen, the second single chain Fv can specifically bind to CD3, and the first and the second single chain Fvs are connected by a linker peptide, while the second single chain Fv and the Fc fragment are directly connected or connected by a linker peptide; and the Fc fragment does not have effector functions such as CDC, ADCC and ADCP.

Abstract: The present invention addresses the problem of limiting power consumption and radio wave interference when assessing the movements of multiple sites of a living body. The present invention is a movement function assessment system provided with: a movement function measurement apparatus for calculating movement data on the basis of the relative distances of pairs of transmission coils and reception coils attached to movable portions of a living body; and an assessment apparatus for assessing the movement function of the living body on the basis of the movement data received from the movement function measurement apparatus. A control unit of the movement function measurement apparatus performs the switching of the multiple transmission coils by a switching unit (1) and the switching of the multiple reception coils by a switching unit (2) so that the paired transmission coils and reception coils are operated sequentially.

Abstract: An object of the present invention is to provide a durometer enabling a contact portion in contact with an object to perform smooth piston motion. The durometer includes a main body unit including a movable unit pressed continuously against an object to be measured, a first sensor outputting acceleration information corresponding to an acceleration of movement of a contact part of the object to be measured in contact with the movable unit in a pressing direction, a second sensor outputting reactive force information corresponding to a reactive force at the contact part of the object to be measured in contact with the movable unit, a motor, a crank mechanism driven by the motor and causing the main body unit and the movable unit to perform piston motion, and at least one buffering member disposed on a periphery of the main body unit.